在現今對於治療生長於主要器官和腦的癌症上，以手術方法往往都是不可行的，因此利用遠端控制釋放的藥物傳遞系統已經有多年的研究，另一方面奈米粒子在藥物傳遞上的發展，能達到高效率的腫瘤標靶和累積，因此結合奈米藥物載體和遠端控制釋放在腫瘤治療上是非常具有潛力的。然而，載體對於腫瘤的穿透能力往往是有限的，腫瘤組織的物理性屏障會降低治療效果，因此增強藥物載體的穿透能力是必須的。本研究中，我們製備出可以應用於外部磁場控制釋放的多孔性金奈米粒子，透過電子顯微鏡 (SEM和TEM) 的觀察可以看出金奈米粒子形狀類似大腦，交錯於表面的條狀構造讓奈米粒子具有孔洞性質，其粒徑可經由對苯二酚 (hydroquinone) 的調控，介於300到400奈米。另外更攜帶載負大量抗癌藥物帕博西林 (palbociclib) 的次級載體-樹枝狀聚合物，經由外部的高週波磁場刺激，這些次級載體能夠攜帶帕博西林穿透腫瘤微球及組織達到治療的目的，此外，多孔性金奈米腦裝載化療藥物/次級載體的裝載量 (loading capacity, LC) 和包覆率 (encapsulation efficiency, EE) 分別為54.3 %和57 %，從細胞實驗結果可以看到，在15和30分鐘的刺激下，細胞存活率可以從90 %降低到10 %。另外，在載體外部修飾上狂犬病蛋白以提升於大腦組織的累積量，提升5 %次級載體的累積量，達到標靶的目的，在動物的存活率實驗中更能延長動物的壽命達到6天。在組織和血液分析中，可以得知攜帶藥物的金奈米腦具有相當低的毒性。因此，經由多孔性金奈米腦搭載攜帶帕博西林的樹枝狀聚合物是非常具有潛力的藥物傳遞平台，能夠經由外部高週波磁場的刺激釋放達到有效的癌症抑制，對於腫瘤的非侵入性治療是非常不錯的選擇。

With the development of drugs encapsulated carriers effectively target and accumulate in cancer cells, the cooperation of nano-therapeutics and remote controlled release are considered as a promising way for tumor treatment. However, the limited ability of tumor penetration due to the physiological barrier of the tumor will restrict efficacy of treatment. Thus, the improvement of nanocarriers on penetrated delivery is needed. In this study, we developed a brain-like porous gold nanoparticle based vehicle as a magnetoelectric agent with high cargo payload. The diameter of the gold nanobrain (GNB) is tunable by altering the concentration of hydroquinone, which range from 300 nm to 400 nm. The cargo is PAMAM dendrimers loaded with cell cycle G1-inhibitor Palbociclib, which can be released under HFMF treatment. The secondary carrier managed to penetrate into tumor spheroids and tumor tissues and deliver Palbociclib for treatment. The loading capacity (LC) and encapsulation efficiency (EE) of GNB encapsulated with Palbociclib-loaded dendrimers (Pal-Den@GNB) were 54.3 % and 57 % respectively. The result of in vitro experiment showed that the viabilities of ALTS1C1 cell line reduced to 10 %. Moreover, with the assistant of RVG, the accumulation of secondary carrier in tumor increased and successfully prolonged the survival rate of brain tumor bearing mice to 6 days. In addition, RVG-Pal-Den@GNB showed low toxicity according to histochemistry and blood analysis. This magnetoelectric release of tumor penetrated delivery platform exhibited excellent performance on tumor inhibition and have a potential for non-invasive treatment application.

1. Lee, C.; Hwang, H. S.; Lee, S.; Kim, B.; Kim, J. O.; Oh, K. T.; Lee, E. S.; Choi, H. G.; Youn, Y. S., Rabies Virus-Inspired Silica-Coated Gold Nanorods as a Photothermal Therapeutic Platform for Treating Brain Tumors. Adv Mater 2017, 29 (13).
2. Wilhelm, S.; Tavares, A. J.; Dai, Q.; Ohta, S.; Audet, J.; Dvorak, H. F.; Chan, W. C. W., Analysis of nanoparticle delivery to tumours. Nature Reviews Materials 2016, 1, 16014.
3. Chen, H. M.; Zhang, W. Z.; Zhu, G. Z.; Xie, J.; Chen, X. Y., Rethinking cancer nanotheranostics. Nature Reviews Materials 2017, 2 (7).
4. Fenton, O. S.; Olafson, K. N.; Pillai, P. S.; Mitchell, M. J.; Langer, R., Advances in Biomaterials for Drug Delivery. Adv Mater 2018, e1705328.
5. Tomalia, D. A.; Reyna, L. A.; Svenson, S., Dendrimers as multi-purpose nanodevices for oncology drug delivery and diagnostic imaging. Biochem Soc T 2007, 35, 61-67.
6. Mishra, V.; Kesharwani, P., Dendrimer technologies for brain tumor. Drug Discov Today 2016, 21 (5), 766-78.
7. Srinageshwar, B.; Peruzzaro, S.; Andrews, M.; Johnson, K.; Hietpas, A.; Clark, B.; McGuire, C.; Petersen, E.; Kippe, J.; Stewart, A.; Lossia, O.; Al-Gharaibeh, A.; Antcliff, A.; Culver, R.; Swanson, D.; Dunbar, G.; Sharma, A.; Rossignol, J., PAMAM Dendrimers Cross the Blood-Brain Barrier When Administered through the Carotid Artery in C57BL/6J Mice. Int J Mol Sci 2017, 18 (3).
8. Tofts, P. S.; Kermode, A. G., Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts. Magn Reson Med 1991, 17 (2), 357-67.
9. Ferrier, M. C.; Sarin, H.; Fung, S. H.; Schatlo, B.; Pluta, R. M.; Gupta, S. N.; Choyke, P. L.; Oldfield, E. H.; Thomasson, D.; Butman, J. A., Validation of dynamic contrast-enhanced magnetic resonance imaging-derived vascular permeability measurements using quantitative autoradiography in the RG2 rat brain tumor model. Neoplasia 2007, 9 (7), 546-55.
10. Sarin, H.; Kanevsky, A. S.; Wu, H.; Brimacombe, K. R.; Fung, S. H.; Sousa, A. A.; Auh, S.; Wilson, C. M.; Sharma, K.; Aronova, M. A.; Leapman, R. D.; Griffiths, G. L.; Hall, M. D., Effective transvascular delivery of nanoparticles across the blood-brain tumor barrier into malignant glioma cells. J Transl Med 2008, 6, 80.
11. Fabel, K.; Dietrich, J.; Hau, P.; Wismeth, C.; Winner, B.; Przywara, S.; Steinbrecher, A.; Ullrich, W.; Bogdahn, U., Long-term stabilization in patients with malignant glioma after treatment with liposomal doxorubicin. Cancer 2001, 92 (7), 1936-42.
12. Discher, D. E.; Eisenberg, A., Polymer vesicles. Science 2002, 297 (5583), 967-73.
13. LoPresti, C.; Lomas, H.; Massignani, M.; Smart, T.; Battaglia, G., Polymersomes: nature inspired nanometer sized compartments. J Mater Chem 2009, 19 (22), 3576-3590.
14. Massignani, M.; Lomas, H.; Battaglia, G., Polymersomes: A Synthetic Biological Approach to Encapsulation and Delivery. Adv Polym Sci 2010, 229, 115-154.
15. Lee, J. S.; Ankone, M.; Pieters, E.; Schiffelers, R. M.; Hennink, W. E.; Feijen, J., Circulation kinetics and biodistribution of dual-labeled polymersomes with modulated surface charge in tumor-bearing mice: comparison with stealth liposomes. J Control Release 2011, 155 (2), 282-8.
16. Massignani, M.; LoPresti, C.; Blanazs, A.; Madsen, J.; Armes, S. P.; Lewis, A. L.; Battaglia, G., Controlling cellular uptake by surface chemistry, size, and surface topology at the nanoscale. Small 2009, 5 (21), 2424-32.
17. Colley, H. E.; Hearnden, V.; Avila-Olias, M.; Cecchin, D.; Canton, I.; Madsen, J.; MacNeil, S.; Warren, N.; Hu, K.; McKeating, J. A.; Armes, S. P.; Murdoch, C.; Thornhill, M. H.; Battaglia, G., Polymersome-mediated delivery of combination anticancer therapy to head and neck cancer cells: 2D and 3D in vitro evaluation. Mol Pharm 2014, 11 (4), 1176-88.
18. Elsadek, B.; Kratz, F., Impact of albumin on drug delivery--new applications on the horizon. J Control Release 2012, 157 (1), 4-28.
19. Elzoghby, A. O.; Samy, W. M.; Elgindy, N. A., Albumin-based nanoparticles as potential controlled release drug delivery systems. Journal of Controlled Release 2012, 157 (2), 168-182.
20. Battogtokh, G.; Ko, Y. T., Active-targeted pH-responsive albumin-photosensitizer conjugate nanoparticles as theranostic agents. J Mater Chem B 2015, 3 (48), 9349-9359.
21. Gu, W.; Zhang, Q.; Zhang, T.; Li, Y. Y.; Xiang, J.; Peng, R.; Liu, J., Hybrid polymeric nano-capsules loaded with gold nanoclusters and indocyanine green for dual-modal imaging and photothermal therapy. J Mater Chem B 2016, 4 (5), 910-919.
22. Jiang, Y. Y.; Lu, H. X.; Dag, A.; Hart-Smith, G.; Stenzel, M. H., Albumin-polymer conjugate nanoparticles and their interactions with prostate cancer cells in 2D and 3D culture: comparison between PMMA and PCL. J Mater Chem B 2016, 4 (11), 2017-2027.
23. Shaikh, B.; Rummel, N.; Reimschuessel, R., Determination of albendazole and its major metabolites in the muscle tissues of Atlantic salmon, tilapia, and rainbow trout by high performance liquid chromatography with fluorometric detection. J Agric Food Chem 2003, 51 (11), 3254-9.
24. Khalilzadeh, A.; Wangoo, K. T.; Morris, D. L.; Pourgholami, M. H., Epothilone-paclitaxel resistant leukemic cells CEM/dEpoB300 are sensitive to albendazole: Involvement of apoptotic pathways. Biochem Pharmacol 2007, 74 (3), 407-14.
25. Pourgholami, M. H.; Khachigian, L. M.; Fahmy, R. G.; Badar, S.; Wang, L.; Chu, S. W.; Morris, D. L., Albendazole inhibits endothelial cell migration, tube formation, vasopermeability, VEGF receptor-2 expression and suppresses retinal neovascularization in ROP model of angiogenesis. Biochem Biophys Res Commun 2010, 397 (4), 729-34.
26. Lu, H. X.; Noorani, L.; Jiang, Y. Y.; Du, A. W.; Stenzel, M. H., Penetration and drug delivery of albumin nanoparticles into pancreatic multicellular tumor spheroids. J Mater Chem B 2017, 5 (48), 9591-9599.
27. Hawkins, M. J.; Soon-Shiong, P.; Desai, N., Protein nanoparticles as drug carriers in clinical medicine. Adv Drug Deliver Rev 2008, 60 (8), 876-885.
28. Podhajcer, O. L.; Benedetti, L.; Girotti, M. R.; Prada, F.; Salvatierra, E.; Llera, A. S., The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host. Cancer Metastasis Rev 2008, 27 (3), 523-37.
29. Sage, H.; Johnson, C.; Bornstein, P., Characterization of a novel serum albumin-binding glycoprotein secreted by endothelial cells in culture. J Biol Chem 1984, 259 (6), 3993-4007.
30. Tonga, G. Y.; Moyano, D. F.; Kim, C. S.; Rotello, V. M., Inorganic Nanoparticles for Therapeutic Delivery: Trials, Tribulations and Promise. Curr Opin Colloid Interface Sci 2014, 19 (2), 49-55.
31. Su, Y. L.; Chen, K. T.; Sheu, Y. C.; Sung, S. Y.; Hsu, R. S.; Chiang, C. S.; Hu, S. H., The Penetrated Delivery of Drug and Energy to Tumors by Lipo-Graphene Nanosponges for Photolytic Therapy. Acs Nano 2016, 10 (10), 9420-9433.
32. Hughes, G. A., Nanostructure-mediated drug delivery. Nanomedicine 2005, 1 (1), 22-30.
33. Wong, C.; Stylianopoulos, T.; Cui, J.; Martin, J.; Chauhan, V. P.; Jiang, W.; Popovic, Z.; Jain, R. K.; Bawendi, M. G.; Fukumura, D., Multistage nanoparticle delivery system for deep penetration into tumor tissue. Proc Natl Acad Sci U S A 2011, 108 (6), 2426-31.
34. Godin, B.; Tasciotti, E.; Liu, X.; Serda, R. E.; Ferrari, M., Multistage nanovectors: from concept to novel imaging contrast agents and therapeutics. Acc Chem Res 2011, 44 (10), 979-89.
35. Parodi, A.; Quattrocchi, N.; van de Ven, A. L.; Chiappini, C.; Evangelopoulos, M.; Martinez, J. O.; Brown, B. S.; Khaled, S. Z.; Yazdi, I. K.; Enzo, M. V.; Isenhart, L.; Ferrari, M.; Tasciotti, E., Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions. Nat Nanotechnol 2013, 8 (1), 61-8.
36. Song, J.; Yang, X.; Jacobson, O.; Lin, L.; Huang, P.; Niu, G.; Ma, Q.; Chen, X., Sequential Drug Release and Enhanced Photothermal and Photoacoustic Effect of Hybrid Reduced Graphene Oxide-Loaded Ultrasmall Gold Nanorod Vesicles for Cancer Therapy. Acs Nano 2015, 9 (9), 9199-209.
37. Su, Y. L.; Fang, J. H.; Liao, C. Y.; Lin, C. T.; Li, Y. T.; Hu, S. H., Targeted Mesoporous Iron Oxide Nanoparticles-Encapsulated Perfluorohexane and a Hydrophobic Drug for Deep Tumor Penetration and Therapy. Theranostics 2015, 5 (11), 1233-48.
38. Libutti, S. K.; Paciotti, G. F.; Byrnes, A. A.; Alexander, H. R., Jr.; Gannon, W. E.; Walker, M.; Seidel, G. D.; Yuldasheva, N.; Tamarkin, L., Phase I and pharmacokinetic studies of CYT-6091, a novel PEGylated colloidal gold-rhTNF nanomedicine. Clin Cancer Res 2010, 16 (24), 6139-49.
39. Dreaden, E. C.; Alkilany, A. M.; Huang, X.; Murphy, C. J.; El-Sayed, M. A., The golden age: gold nanoparticles for biomedicine. Chem Soc Rev 2012, 41 (7), 2740-79.
40. Morshed, R. A.; Muroski, M. E.; Dai, Q.; Wegscheid, M. L.; Auffinger, B.; Yu, D.; Han, Y.; Zhang, L.; Wu, M.; Cheng, Y.; Lesniak, M. S., Cell-Penetrating Peptide-Modified Gold Nanoparticles for the Delivery of Doxorubicin to Brain Metastatic Breast Cancer. Mol Pharm 2016, 13 (6), 1843-54.
41. Brooks, N.; Esparon, S.; Pouniotis, D.; Pietersz, G. A., Comparative Immunogenicity of a Cytotoxic T Cell Epitope Delivered by Penetratin and TAT Cell Penetrating Peptides. Molecules 2015, 20 (8), 14033-50.
42. Koren, E.; Apte, A.; Sawant, R. R.; Grunwald, J.; Torchilin, V. P., Cell-penetrating TAT peptide in drug delivery systems: proteolytic stability requirements. Drug Deliv 2011, 18 (5), 377-84.
43. Li, H.; Tsui, T. Y.; Ma, W. X., Intracellular Delivery of Molecular Cargo Using Cell-Penetrating Peptides and the Combination Strategies. International Journal of Molecular Sciences 2015, 16 (8), 19518-19536.
44. Salzano, G.; Torchilin, V. P., Intracellular Delivery of Nanoparticles with Cell Penetrating Peptides. Methods Mol Biol 2015, 1324, 357-68.
45. Raucher, D.; Ryu, J. S., Cell-penetrating peptides: strategies for anticancer treatment. Trends Mol Med 2015, 21 (9), 560-70.
46. Ryu, J. S.; Raucher, D., Elastin-like polypeptide for improved drug delivery for anticancer therapy: preclinical studies and future applications. Expert Opin Drug Deliv 2015, 12 (4), 653-67.
47. Cantini, L.; Attaway, C. C.; Butler, B.; Andino, L. M.; Sokolosky, M. L.; Jakymiw, A., Fusogenic-oligoarginine peptide-mediated delivery of siRNAs targeting the CIP2A oncogene into oral cancer cells. PLoS One 2013, 8 (9), e73348.
48. Savariar, E. N.; Felsen, C. N.; Nashi, N.; Jiang, T.; Ellies, L. G.; Steinbach, P.; Tsien, R. Y.; Nguyen, Q. T., Real-time in vivo molecular detection of primary tumors and metastases with ratiometric activatable cell-penetrating peptides. Cancer Res 2013, 73 (2), 855-64.
49. Crisp, J. L.; Savariar, E. N.; Glasgow, H. L.; Ellies, L. G.; Whitney, M. A.; Tsien, R. Y., Dual targeting of integrin alphavbeta3 and matrix metalloproteinase-2 for optical imaging of tumors and chemotherapeutic delivery. Mol Cancer Ther 2014, 13 (6), 1514-25.
50. Tannock, I. F.; Rotin, D., Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res 1989, 49 (16), 4373-84.
51. Kale, A. A.; Torchilin, V. P., Environment-responsive multifunctional liposomes. Methods Mol Biol 2010, 605, 213-42.
52. Wang, H. X.; Yang, X. Z.; Sun, C. Y.; Mao, C. Q.; Zhu, Y. H.; Wang, J., Matrix metalloproteinase 2-responsive micelle for siRNA delivery. Biomaterials 2014, 35 (26), 7622-34.
53. Klein, T.; Bischoff, R., Physiology and pathophysiology of matrix metalloproteases. Amino Acids 2011, 41 (2), 271-90.
54. Roy, R.; Yang, J.; Moses, M. A., Matrix Metalloproteinases As Novel Biomarkers and Potential Therapeutic Targets in Human Cancer. J Clin Oncol 2009, 27 (31), 5287-5297.
55. Yu, X. F.; Han, Z. C., Matrix metalloproteinases in bone marrow: roles of gelatinases in physiological hematopoiesis and hematopoietic malignancies. Histol Histopathol 2006, 21 (5), 519-31.
56. Li, H.; Lee, T.; Dziubla, T.; Pi, F. M.; Guo, S. J.; Xu, J.; Li, C.; Haque, F.; Liang, X. J.; Guo, P. X., RNA as a stable polymer to build controllable and defined nanostructures for material and biomedical applications. Nano Today 2015, 10 (5), 631-655.
57. Jang, M.; Han, H. D.; Ahn, H. J., A RNA nanotechnology platform for a simultaneous two-in-one siRNA delivery and its application in synergistic RNAi therapy. Sci Rep 2016, 6, 32363.
58. Dean, M.; Rzhetsky, A.; Allikmets, R., The human ATP-binding cassette (ABC) transporter superfamily. Genome Res 2001, 11 (7), 1156-66.
59. Leonard, G. D.; Fojo, T.; Bates, S. E., The role of ABC transporters in clinical practice. Oncologist 2003, 8 (5), 411-24.
60. Szakacs, G.; Paterson, J. K.; Ludwig, J. A.; Booth-Genthe, C.; Gottesman, M. M., Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006, 5 (3), 219-34.
61. Schinkel, A. H.; Jonker, J. W., Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev 2003, 55 (1), 3-29.
62. Kitada, S.; Andersen, J.; Akar, S.; Zapata, J. M.; Takayama, S.; Krajewski, S.; Wang, H. G.; Zhang, X.; Bullrich, F.; Croce, C. M.; Rai, K.; Hines, J.; Reed, J. C., Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with In vitro and In vivo chemoresponses. Blood 1998, 91 (9), 3379-89.
63. Nita, M. E.; Nagawa, H.; Tominaga, O.; Tsuno, N.; Fujii, S.; Sasaki, S.; Fu, C. G.; Takenoue, T.; Tsuruo, T.; Muto, T., 5-Fluorouracil induces apoptosis in human colon cancer cell lines with modulation of Bcl-2 family proteins. Br J Cancer 1998, 78 (8), 986-92.
64. Nguyen, S. C.; Zhang, Q.; Manthiram, K.; Ye, X.; Lomont, J. P.; Harris, C. B.; Weller, H.; Alivisatos, A. P., Study of Heat Transfer Dynamics from Gold Nanorods to the Environment via Time-Resolved Infrared Spectroscopy. Acs Nano 2016, 10 (2), 2144-51.
65. Tan, S. F.; Anand, U.; Mirsaidov, U., Interactions and Attachment Pathways between Functionalized Gold Nanorods. Acs Nano 2017, 11 (2), 1633-1640.
66. Xu, C.; Yang, D.; Mei, L.; Lu, B.; Chen, L.; Li, Q.; Zhu, H.; Wang, T., Encapsulating gold nanoparticles or nanorods in graphene oxide shells as a novel gene vector. ACS Appl Mater Interfaces 2013, 5 (7), 2715-24.
67. Burrows, N. D.; Lin, W.; Hinman, J. G.; Dennison, J. M.; Vartanian, A. M.; Abadeer, N. S.; Grzincic, E. M.; Jacob, L. M.; Li, J.; Murphy, C. J., Surface Chemistry of Gold Nanorods. Langmuir 2016, 32 (39), 9905-9921.
68. Chen, H. Y.; Abraham, S.; Mendenhall, J.; Delamarre, S. C.; Smith, K.; Kim, I.; Batt, C. A., Encapsulation of single small gold nanoparticles by diblock copolymers. Chemphyschem 2008, 9 (3), 388-92.
69. Abadeer, N. S.; Brennan, M. R.; Wilson, W. L.; Murphy, C. J., Distance and plasmon wavelength dependent fluorescence of molecules bound to silica-coated gold nanorods. Acs Nano 2014, 8 (8), 8392-406.
70. Xu, C.; Chen, F.; Valdovinos, H. F.; Jiang, D.; Goel, S.; Yu, B.; Sun, H.; Barnhart, T. E.; Moon, J. J.; Cai, W., Bacteria-like mesoporous silica-coated gold nanorods for positron emission tomography and photoacoustic imaging-guided chemo-photothermal combined therapy. Biomaterials 2018, 165, 56-65.
71. Vivero-Escoto, J. L.; Slowing, II; Wu, C. W.; Lin, V. S., Photoinduced intracellular controlled release drug delivery in human cells by gold-capped mesoporous silica nanosphere. J Am Chem Soc 2009, 131 (10), 3462-3.
72. Han, G.; You, C. C.; Kim, B. J.; Turingan, R. S.; Forbes, N. S.; Martin, C. T.; Rotello, V. M., Light-regulated release of DNA and its delivery to nuclei by means of photolabile gold nanoparticles. Angew Chem Int Ed Engl 2006, 45 (19), 3165-9.
73. Xie, S.; Ma, F.; Liu, Y.; Li, J., Multiferroic CoFe2O4-Pb(Zr(0.52)Ti(0.48))O3 core-shell nanofibers and their magnetoelectric coupling. Nanoscale 2011, 3 (8), 3152-8.
74. Szebeni, J.; Wahl, S. M.; Betageri, G. V.; Wahl, L. M.; Gartner, S.; Popovic, M.; Parker, R. J.; Black, C. D.; Weinstein, J. N., Inhibition of HIV-1 in monocyte/macrophage cultures by 2',3'-dideoxycytidine-5'-triphosphate, free and in liposomes. AIDS Res Hum Retroviruses 1990, 6 (5), 691-702.
75. Varatharajan, L.; Thomas, S. A., The transport of anti-HIV drugs across blood-CNS interfaces: summary of current knowledge and recommendations for further research. Antiviral Res 2009, 82 (2), A99-109.
76. Nair, M.; Guduru, R.; Liang, P.; Hong, J.; Sagar, V.; Khizroev, S., Externally controlled on-demand release of anti-HIV drug using magneto-electric nanoparticles as carriers. Nat Commun 2013, 4, 1707.
77. Griffith, L. G.; Swartz, M. A., Capturing complex 3D tissue physiology in vitro. Nat Rev Mol Cell Biol 2006, 7 (3), 211-24.
78. Han, B.; Qu, C.; Park, K.; Konieczny, S. F.; Korc, M., Recapitulation of complex transport and action of drugs at the tumor microenvironment using tumor-microenvironment-on-chip. Cancer Lett 2016, 380 (1), 319-29.
79. Lazzari, G.; Couvreur, P.; Mura, S., Multicellular tumor spheroids: a relevant 3D model for the in vitro preclinical investigation of polymer nanomedicines. Polym Chem-Uk 2017, 8 (34), 4947-4969.
80. Benien, P.; Swami, A., 3D tumor models: history, advances and future perspectives. Future Oncol 2014, 10 (7), 1311-27.
81. Jin, H. J.; Cho, Y. H.; Gu, J. M.; Kim, J.; Oh, Y. S., A multicellular spheroid formation and extraction chip using removable cell trapping barriers. Lab Chip 2011, 11 (1), 115-9.
82. Bhise, N. S.; Ribas, J.; Manoharan, V.; Zhang, Y. S.; Polini, A.; Massa, S.; Dokmeci, M. R.; Khademhosseini, A., Organ-on-a-chip platforms for studying drug delivery systems. J Control Release 2014, 190, 82-93.
83. Hayashi, K.; Tabata, Y., Preparation of stem cell aggregates with gelatin microspheres to enhance biological functions. Acta Biomater 2011, 7 (7), 2797-803.
84. Huang, Y. C.; Chan, C. C.; Lin, W. T.; Chiu, H. Y.; Tsai, R. Y.; Tsai, T. H.; Chan, J. Y.; Lin, S. J., Scalable production of controllable dermal papilla spheroids on PVA surfaces and the effects of spheroid size on hair follicle regeneration. Biomaterials 2013, 34 (2), 442-51.
85. Chen, Y.; Gao, D.; Liu, H.; Lin, S.; Jiang, Y., Drug cytotoxicity and signaling pathway analysis with three-dimensional tumor spheroids in a microwell-based microfluidic chip for drug screening. Anal Chim Acta 2015, 898, 85-92.
86. Zuchowska, A.; Jastrzebska, E.; Chudy, M.; Dybko, A.; Brzozka, Z., 3D lung spheroid cultures for evaluation of photodynamic therapy (PDT) procedures in microfluidic Lab-on-a-Chip system. Anal Chim Acta 2017, 990, 110-120.